The University of Pittsburgh Alzheimer's Disease Research Center (PITT-ADRC) has shown a clear scientific evolution over the past three decades. Since our inception, we have advanced the areas of AD neuropsychiatry, the natural history of AD, validation of clinical criteria, and clinico-pathological correlations. We have pioneered new positron emission technology (PET) techniques for amyloid imaging. We have used a multidisciplinary approach to better understand the transition from normalcy to dementia, have explored the biology of more aggressive forms of AD characterized by psychosis, and have made and contributed to new insights in genetics. This solid scientific background has allowed the PITT-ADRC to develop areas of excellence, which will serve as the basis for the future of the Center. These are reflected in the Center's cores and projects, and most notably in the large number of studies we support in Pittsburgh and at the national and international level. Equally important, the availability of a rich, multidisciplinary training environment along with dedicated, skilled mentoring creates the ?perfect laboratory? to develop and advance young investigators. With our Projects, we are committed to remain at the forefront of the scientific efforts to understand the pathological processes involved in the etiology of AD. Project-1 takes a comprehensive neuroimaging approach to studying subjective cognitive decline (in the context of personality factors), with a focus on amyloid PET imaging as the putative earliest indicator of AD pathology. Project-2 will combine amyloid PET and a measure of synaptic density (11C- UCB-J) to examine pathological status of cognitively normal control subjects who are amyloid- negative but already show hypometabolism or hippocampal atrophy. Project 3 will examine the pathological basis of psychotic symptoms in AD patients, which have a tremendous effect on the quality of life of the patients and their families, and are risk factors for rapid clinical progression of the disease and mortality. The PITT-ADRC, through its pilot projects, engages and involves as many clinical and basic researchers as possible. This extends to all aspects of research relevant to AD and related dementias. The goal of this Revision application is to augment the acquisition of brain imaging data (both MRI and PET), standardize the analysis of all imaging data acquired from ADRC participants, and to make these data available to ADRC investigators, collaborators, and large data repositories (e.g., NACC, ENIGMA) for further analysis.

Public Health Relevance

The University of Pittsburgh Alzheimer's Disease Research Center (PITT-ADRC) aims to be a focal point of innovative research on the cause and effective treatment of Alzheimer's disease (AD). While serving as a local resource for outreach, education and support to patients and caregivers at all stages of the disease, we focus our research efforts on the transition from normal aging into the earliest detectable stages of cognitive decline and have pioneered transformative amyloid imaging technology to facilitate these efforts here and around the world. At the PITT-ADRC, we strive to accomplish our goal through: 1) our own research; 2) involving affiliated investigators at the University of Pittsburgh and nearby institutions in both clinical and basic research; 3) collaborations with other members of the Centers Program; and 4) collaborations with other national and international centers of excellence in AD. The purpose of this Revision of our NeuroImaging Core is to expand the brain imaging data and the data analysis capabilities of the Core to meet the needs of the Center for the next 5-10 years.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Qiu, Shangran; Chang, Gary H; Panagia, Marcello et al. (2018) Fusion of deep learning models of MRI scans, Mini-Mental State Examination, and logical memory test enhances diagnosis of mild cognitive impairment. Alzheimers Dement (Amst) 10:737-749
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
DeMichele-Sweet, M A A; Weamer, E A; Klei, L et al. (2018) Genetic risk for schizophrenia and psychosis in Alzheimer disease. Mol Psychiatry 23:963-972
Wilckens, Kristine A; Tudorascu, Dana L; Snitz, Beth E et al. (2018) Sleep moderates the relationship between amyloid beta and memory recall. Neurobiol Aging 71:142-148
Di Maio, Roberto; Hoffman, Eric K; Rocha, Emily M et al. (2018) LRRK2 activation in idiopathic Parkinson's disease. Sci Transl Med 10:

Showing the most recent 10 out of 667 publications